Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Classical hematology 1Breast 1

Conditions

Breast Neoplasms 4Neutropenia 3Febrile Neutropenia 3Small Cell Lung Carcinoma 1Patients With Nonmyeloid Malignancies Receiving Antineoplastic Therapy Based on Chemotherapy Regimens at Moderate to High Febrile Neutropenia (FN) Risk 1Malignant Solid Tumors 1Lymphoma, Non-Hodgkin 1Lymphoma 1Chemotherapy-induced Neutropenia 1Carcinoma, Non-Small-Cell Lung 1Breast Cancer Female 1Advanced Pancreatic Cancer 1

Interventions

Carboplatin 367Pemetrexed 308pembrolizumab 302Cisplatin 242Paclitaxel 230Docetaxel 199Gemcitabine 130Nivolumab 121Erlotinib Hydrochloride 114Bevacizumab 85osimertinib 78atezolizumab 65durvalumab 58Cetuximab 57130-nm albumin-bound paclitaxel 56Gefitinib 52Ipilimumab 46Afatinib 38Drug Therapy 33Cyclophosphamide 30Crizotinib 30Albumin-Bound Paclitaxel 30Vinorelbine 28cemiplimab 26tislelizumab 25avelumab 23icotinib 22Radiotherapy 22capmatinib 21Oxaliplatin 21

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Carcinoma, Non-Small-Cell Lung × pegylated granulocyte colony-stimulating factor × Clear all
NCT02005458 2018-07-17

Safety and Efficacy of YPEG-rhG-CSF in Cancer Patients Receiving Chemotherapy

Xiamen Amoytop Biotech Co., Ltd.

Phase 2 Completed
80 enrolled
BreastClassical hematologyThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Neutropenia, Febrile Neutropenia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡